CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...

Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...

AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, ...